2022
DOI: 10.1073/pnas.2200544119
|View full text |Cite
|
Sign up to set email alerts
|

The solute carrier SLC15A4 is required for optimal trafficking of nucleic acid–sensing TLRs and ligands to endolysosomes

Abstract: Significance A large body of evidence has indicated that recognition of self-nucleic acids by endosomal toll-like receptors (TLRs) is central to the pathogenesis of lupus-like systemic autoimmunity in spontaneous mouse models, and the solute carrier SLC15A4 is required for this recognition. Here we describe a mechanism in which SLC15A4 is a major contributor to the proper trafficking of TLRs and their ligands to endolysosomes, wherein recognition and signaling is initiated. This finding supports ongo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
26
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 29 publications
(26 citation statements)
references
References 53 publications
(83 reference statements)
0
26
0
Order By: Relevance
“…Here, we report the development of, to our knowledge, the first SLC15A4 inhibitors. We demonstrate that our lead compound, AJ2-30, engages SLC15A4 directly in primary immune cells, inhibits TLR7-9 signaling pathways and cytokine production as well as SLC15A4-mediated NOD 1/2 activation in primary human and mouse immune cells, key functions regulated by SLC15A4 ( 1, 4, 5, 8-10 ). Our findings suggest that pharmacological inhibition of SLC15A4 results in disruption of an mTOR-IRF circuit essential for IFN-I and other inflammatory cytokine production, however the molecular details of how SLC15A4 modulates this pathway are not yet elucidated.…”
Section: Main Textmentioning
confidence: 79%
See 2 more Smart Citations
“…Here, we report the development of, to our knowledge, the first SLC15A4 inhibitors. We demonstrate that our lead compound, AJ2-30, engages SLC15A4 directly in primary immune cells, inhibits TLR7-9 signaling pathways and cytokine production as well as SLC15A4-mediated NOD 1/2 activation in primary human and mouse immune cells, key functions regulated by SLC15A4 ( 1, 4, 5, 8-10 ). Our findings suggest that pharmacological inhibition of SLC15A4 results in disruption of an mTOR-IRF circuit essential for IFN-I and other inflammatory cytokine production, however the molecular details of how SLC15A4 modulates this pathway are not yet elucidated.…”
Section: Main Textmentioning
confidence: 79%
“…Mouse cells were isolated from a single cell suspension of mouse splenocytes, coming from either Wild-type C57BL/6J or feeble mice (PMID: 21045126)( 5 ) which had been back-crossed onto the C57BL/6J line. Mouse immune cells were isolated using corresponding isolation kits from StemCell Technologies.…”
Section: Supplementary Materialsmentioning
confidence: 99%
See 1 more Smart Citation
“…SLC15A4 is required for TLR7 and TLR9 responses in pDCs ( 52 ). It also mediates AP3-dependent endosomal trafficking required for TLR7 and TLR9 responses ( 53 ). Moreover, SLC15A4 serves as a scaffold protein by associating with TLR adaptor interacting with SLC15A4 on the lysosome (TASL) ( 54 ), which recruits IRFs to transmit signals from TLR7, TLR8, and TLR9.…”
Section: Introductionmentioning
confidence: 99%
“…Several reports have linked the solute carrier 15 (SLC15) family of peptide transporters to cytosolic muropeptide delivery (16)(17)(18)(19)(20)(21). However, these solute carriers have not been directly demonstrated to transport muropeptides and are not specifically required for NOD signaling, but instead have recently been linked to IRF5 activation following stimulation of TLRs as well as NODs (22,23). On the other hand, we recently identified the SLC46 family as candidate muropeptide transporters in Drosophila and mammalian cells (24).…”
Section: Introductionmentioning
confidence: 99%